Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This week tags : Study save search
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | News | $11.64 -3.4% -3.52% 270K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
jeuveau publication for study
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Published: 2024-04-17 (Crawled : 16:00) - biospace.com/
HYPR | News | $0.9129 -7.79% -8.45% 80K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -8.08%
first alzheimer’s care enroll therapy study
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | News | $39.66 2.75% 2.67% 910K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $12.585 -19.48% -24.2% 4.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
ATAI | News | $1.98 -7.91% -8.59% 1.5M
|
Manufacturing
|
| O: 4.87%
H: 0.0%
C: 0.0%
bpl-003 life publication sciences study
Every Rand Lost to Fraud in South Africa Costs Firms R3.64 According to LexisNexis True Cost of Fraud Study
Published: 2024-04-17 (Crawled : 07:00) - prnewswire.com
RELX | News | $41.45 0.41% 0.0% 750K
|
Commercial Services
|
| O: 1.11%
H: 0.0%
C: -1.05%
lexisnexis africa study
Every Dirham Lost to Fraud in UAE Costs Firms AED$4.19 According to LexisNexis True Cost of Fraud Study
Published: 2024-04-17 (Crawled : 05:00) - prnewswire.com
RELX | News | $41.45 0.41% 0.0% 750K
|
Commercial Services
|
| O: 1.11%
H: 0.0%
C: -1.05%
lexisnexis study
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN | News F | $18.66 -1.37% -1.39% 550K
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
prequel positive for study
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
PALI | $6.54 10.29% 9.33% 1.6M
|
Manufacturing
|
| O: 113.15%
H: 10.29%
C: -32.23%
pali-2108 study
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
CMPX | $1.52 -3.19% -3.29% 120K
|
Professional, Scientific, and T...
|
| O: 2.93%
H: 3.8%
C: -0.63%
ctx-8371 first tumors therapeutics study
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
BRTX | $1.37 4.58% 4.38% 660K
|
Professional, Scientific, and T...
|
| O: 9.23%
H: 15.49%
C: -7.75%
brtx-100 fda clearance study
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI 1 d | $76.68 -3.96% -4.12% 2.9M
|
Health Technology
|
| O: 14.75%
H: 12.75%
C: 6.04%
positive topline therapy results study
Descartes’ Study Reveals 54% of Supply Chain and Logistics Operations are Prioritizing Automation to Mitigate Workforce Shortages
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
DSGX | $90.51 -0.43% -0.43% 260K
|
Technology Services
|
| O: -1.18%
H: 0.0%
C: 0.0%
study
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
NMRA | $10.575 -3.51% -3.64% 610K
|
|
| O: -20.17%
H: 11.46%
C: 0.99%
nmra-266 therapeutics study
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7448 -3.51% -3.64% 3.1M
|
Health Technology
|
| O: -6.28%
H: 1.25%
C: -13.83%
vaccine results study platform
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.